scholarly journals TREATMENT OF PRESSURE ULCERS IN PATIENTS WITH SPINAL CORD INJURY: CONVENTIONAL SURGERY vs. CELLULAR THERAPY

2021 ◽  
Vol 108 (Supplement_3) ◽  
Author(s):  
C Burgos Gutiérrez ◽  
P Álvarez-Buylla Álvarez ◽  
M Álvarez Viejo ◽  
S Pérez López ◽  
M Pérez Basterrechea ◽  
...  
Keyword(s):  
Spinal Cord ◽  
Bone Marrow ◽  
Mononuclear Cell ◽  
Pressure Ulcers ◽  
Mononuclear Cells ◽  
Bone Marrow Mononuclear Cell ◽  
Conventional Surgery ◽  
Surgery Group ◽  
Cord Injury ◽  
One Year

Abstract INTRODUCTION Relapse rates of pressure ulcers (PUs) are very high in spinal cord injured patients. That is the reason why alternative therapies, such as using stem cells derived from bone marrow, have been developed. The objective of our study is to compare this technique of infiltration - infusion of mononuclear cells with conventional surgery. MATERIAL AND METHODS A retrospective study was carried out in patients with spinal cord injuries who had PUs, category III / IV, in the pelvic area, during a 14-year follow-up period. One group was treated with conventional surgery and, in the other group, mononuclear cells were infused. The statistical analysis was done using the R program and level of significance used was <0.05. RESULTS One hundred and forty-nine patients were registered, 42.3% in the conventional surgery group and 57.7% in the mononuclear cell group. There were no significant differences in terms of ulcer healing in the first six months, but 6 months and one year post-treatment, it were found significant differences. At 6 months, no patient in the conventional surgery group presented dehiscence of the wound and, one year after surgery, only 3.17% recurred in the conventional group In addition, it was shown that there was a statistically significant relationship between days of hospitalization and type of bacterial contamination and the intervention group. CONCLUSIONS Use of bone marrow mononuclear cell infusion-infiltration is an alternative treatment for PUs during the first 6 months, instead of conventional surgery. However, in the medium-long term, conventional surgery is more effective.

scholarly journals Efficacy of autologous bone marrow mononuclear cell transplantation in dogs with chronic spinal cord injury

2020 ◽  
Vol 10 (2) ◽  
pp. 206-215
Author(s):  
Katsutoshi Tamura ◽  
Noritaka Maeta
Keyword(s):  
Spinal Cord ◽  
Bone Marrow ◽  
Spinal Cord Injury ◽  
Cell Transplantation ◽  
Mononuclear Cell ◽  
Motor Neurons ◽  
Research Work ◽  
Autologous Bone Marrow ◽  
Bone Marrow Mononuclear Cell ◽  
Cord Injury

Background: Spinal cord injury (SCI) is relatively common in dogs and is a devastating condition involving loss of sensory neurons and motor  neurons. However, the main clinical protocol for the management of SCI is surgery to decompress and stabilize the vertebra. Cell transplantation therapy is a very promising strategy for the treatment of chronic SCI, but extensive preclinical and clinical research work remains.Aim: The aim of this study is to confirm the effect of bone marrow-derived mononuclear cell (BM-MNC) transplantation for chronic SCI in dogs.Methods: We tested the treatment efficiency of chronic SCI in 12 dogs using BM-MNC transplantation. Neurological evaluation used the Texas Spinal Cord Injury Scale (TSCIS). Concurrently, we characterized the transplanted cells by evaluation using quantitative real-time polymerase chain reaction, flow cytometry, and enzyme-linked immunosorbent assay.Result: All dogs had a pre-transplantation TSCIS score of 0. Two animals did not show any improvement in their final TSCIS scores. The remaining 10 dogs (83.4%) achieved improvement in the final TSCIS scores. Five of them (41.7%) regained ambulatory function with a TSCIS score greater than 10. We determined that canine BM-MNCs expressed hepatocyte growth factor (HGF) mRNA at higher levels than other cytokines, with significant  increases in HGF levels in cerebrospinal fluid within 48 hours after autologous BM-MNC transplantation into the subarachnoid space of the spinal dura matter in dogs.Conclusions: BM-MNC transplantation may be effective for at least some cases of chronic SCI. Keywords: Bone marrow-derived mononuclear cell, Cell therapy, Spinal cord injury.

scholarly journals Two intrathecal transplants of bone marrow mononuclear cells produce motor improvement in an acute and severe model of spinal cord injury

2013 ◽  
Vol 12 (4) ◽  
pp. 274-277 ◽  
Author(s):  
Elisa Lettnin Kaminski ◽  
Asdrubal Falavigna ◽  
Gianina Terribele Venturin ◽  
Daniel Marinowic ◽  
Pamela Brambilla Bagatini ◽  
...  
Keyword(s):  
Spinal Cord ◽  
Bone Marrow ◽  
Spinal Cord Injury ◽  
Motor Function ◽  
Histological Analysis ◽  
Mononuclear Cells ◽  
Pcr Analysis ◽  
Bone Marrow Mononuclear Cells ◽  
Injury Site ◽  
Cord Injury

OBJECTIVE: We studied transplants of bone marrow mononuclear cells (BMMC) by lumbar puncture (LP) in a severe model of spinal cord injury (SCI) using clip compression. METHODS: BMMCs or saline solution were transplanted by LP 48 hours and 9 days post injury. Motor function was evaluated by BBB scale, histological analysis by Nissl technique and the verification of cell migration by PCR analysis. RESULTS: The BBB had significantly improved in rats treated with BMMCs by LP compared with controls (p<0.001). The histological analysis did not showed difference in the lesional area between the groups. The PCR analysis was able to found BMMCs in the injury site. CONCLUSIONS: two BMMC transplants by LP improved motor function in a severe model of SCI and BMMC was found in the injury site.

Bone marrow-derived mononuclear cell transplantation in spinal cord injury patients by lumbar puncture

2014 ◽  
Vol 32 (4) ◽  
pp. 473-482 ◽  
Author(s):  
Yoshihisa Suzuki ◽  
Namiko Ishikawa ◽  
Kaoru Omae ◽  
Tatsuya Hirai ◽  
Katsunori Ohnishi ◽  
...  
Keyword(s):  
Spinal Cord ◽  
Bone Marrow ◽  
Spinal Cord Injury ◽  
Lumbar Puncture ◽  
Cell Transplantation ◽  
Mononuclear Cell ◽  
Cord Injury

Potential of combination of bone marrow nucleated and mesenchymal stem cells in complete spinal cord injury

2020 ◽  
Vol 15 ◽  
Author(s):  
Shojiro Katoh ◽  
Vidyasagar Devaprasad Dedeepiya ◽  
Satoshi Kuroda ◽  
Masaru Iwasaki ◽  
Rajappa Senthilkumar ◽  
...  
Keyword(s):  
Spinal Cord ◽  
Stem Cells ◽  
Bone Marrow ◽  
Mesenchymal Stem Cells ◽  
Animal Studies ◽  
Mononuclear Cells ◽  
Cell Types ◽  
Definitive Treatment ◽  
Spinal Cord Regeneration ◽  
Cord Injury

Background: Cell-based therapies represent one of the definitive treatment approaches to SCI which to become a routine clinical application is marred by several known unknowns. The bone marrow mononuclear cells (BMMNCs) and mesenchymal stem cells (MSCs) represent the most clinically applied cell types for SCI in humans, with safety established and to an extent, efficacy reported. Methods: In this review we have analysed the clinical studies done using BMMNC and MSC for complete SCI separately and the potential for applying those cells in combination. We have also analysed those factors whose outcome in animal studies of SCI could be evaluated in depth but the clinical outcome cannot be evaluated intrinsically owing to practical difficulties. Conclusion: A combination of these two cell types, BMMNC and MSC has been proven to be advantageous than applying them separately. Therefore, a thorough evaluation including rationale and potential implications of applying these two therapies has been presented here and we hypothesize that such a combination is likely to improvise the outcome of a wholesome approach to spinal cord regeneration after SCI.

Neuroprotective Effect of Bone Marrow–Derived Mononuclear Cells Promoting Functional Recovery from Spinal Cord Injury

2007 ◽  
Vol 24 (6) ◽  
pp. 1026-1036 ◽  
Author(s):  
Tomoyuki Yoshihara ◽  
Masayoshi Ohta ◽  
Yutaka Itokazu ◽  
Naoya Matsumoto ◽  
Mari Dezawa ◽  
...  
Keyword(s):  
Spinal Cord ◽  
Bone Marrow ◽  
Spinal Cord Injury ◽  
Functional Recovery ◽  
Mononuclear Cells ◽  
Neuroprotective Effect ◽  
Cord Injury

Delivery of Autologous Bone Marrow Precursor Cells into the Spinal Cord Via Lumbar Puncture Technique in Patients with Spinal Cord Injury.

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 5204-5204
Author(s):  
Fernando Callera
Keyword(s):  
Spinal Cord ◽  
Bone Marrow ◽  
Mononuclear Cells ◽  
Autologous Bone Marrow ◽  
Precursor Cells ◽  
Therapeutic Effects ◽  
Bone Marrow Precursor ◽  
Cd34 Cells ◽  
Cord Injury ◽  
Autologous Bone

Abstract Alternative and less invasive routes for delivering hematopoietic stem cells in animals models of spinal cord injury (SCI) were described and the advantages of the percutaneous lumbar puncture (LP) technique have been recently demonstrated. (Bakshi A et al. 2004, Lepore AC et al. 2005) This proposition has not been described in humans. We therefore tested it by examining whether autologous bone marrow precursor cells can be delivered into the spinal cord via LP in patients with SCI. Seven patients with SCI (four had paraplegia and three had quadriplegia) were enrolled. The median age was 24 years and the mean duration of injury was 3 years. Patients received G-CSF (10microg/Kg) for five consecutive days and 100mL of bone marrow cells (BMC) were aspirated from the posterior iliac crest on day 6. Patients provided written informed consent. Mononuclear cells were separated by a Ficoll-Hypaque gradient, washed and resuspended in PBS. Flow cytometric enumeration of CD34+ cells was performed as previously described. (Gratama JW et al. 2001) Transplantation was performed 4 hours after bone marrow aspiration. CSF samples were collected before and seven days after the transplantation. For each patient, 15x106 mononuclear cells were injected via LP; the median number of CD34+ cells was 2.5x105 (1.8–5.0x105). Cell viability before transplantation was superior to 90% in all samples. Patients had no adverse events. CSF examination was normal in both times. Bone marrow precursor cells are clinically attractive because they can be obtained in patients at bedside raising the possibility of an autologous model of cell therapy for SCI. However, the potential therapeutic effects of these cells for SCI are poorly understood. What is the optimal CD34+ cell dosage? Will multiple doses of CD34+ cells be more efficacious? Is CD34+ the most appropriate BMC subset? Will BMC subsets combinations be more efficacious? The follow-up of our patients will probably provide some information. The absence of cells in CSF samples obtained after seven days is also intriguing. Although high speculative, a possible explanation is that cells home toward the injured spinal cord. All these issues need to be resolved in carefully designed experiments. Finally, our study demonstrated the possibility of delivering autologous bone marrow precursor cells via LP in patients with SCI. This procedure is feasible, safe and well-tolerated in humans. The potential therapeutic effects of these cells for SCI remain to be elucidated.

Effects of Multiple Injection of Bone Marrow Mononuclear Cells on Spinal Cord Injury of Rats

2017 ◽  
Vol 34 (21) ◽  
pp. 3003-3011 ◽  
Author(s):  
Kenji Kanekiyo ◽  
Norihiko Nakano ◽  
Tamami Homma ◽  
Yoshihiro Yamada ◽  
Masahiro Tamachi ◽  
...  
Keyword(s):  
Spinal Cord ◽  
Bone Marrow ◽  
Spinal Cord Injury ◽  
Mononuclear Cells ◽  
Bone Marrow Mononuclear Cells ◽  
Multiple Injection ◽  
Cord Injury

scholarly journals Index of CD34+ Cells and Mononuclear Cells in the Bone Marrow of Spinal Cord Injury Patients of Different Age Groups: A Comparative Analysis

2012 ◽  
Vol 2012 ◽  
pp. 1-8 ◽  
Author(s):  
Vidyasagar Devaprasad Dedeepiya ◽  
Yegneswara Yellury Rao ◽  
Gosalakkal A. Jayakrishnan ◽  
Jutty K. B. C. Parthiban ◽  
Subramani Baskar ◽  
...  
Keyword(s):  
Spinal Cord ◽  
Bone Marrow ◽  
Spinal Cord Injury ◽  
General Population ◽  
Mononuclear Cells ◽  
Age Groups ◽  
Reproductive Age ◽  
Cd34 Cells ◽  
Cord Injury ◽  
And Gender

Introduction. Recent evidence of safety and efficacy of Bone Marrow Mononuclear Cells (BMMNC) in spinal cord injury makes the Bone Marrow (BM) CD34+ percentage and the BMMNC count gain significance. The indices of BM that change with body mass index and aging in general population have been reported but seldom in Spinal Cord Injury (SCI) victims, whose parameters of relevance differ from general population. Herein, we report the indices of BMMNC in SCI victims. Materials and Methods. BMMNCs of 332 SCI patients were isolated under GMP protocols. Cell count by Trypan blue method and CD34+ cells by flow cytometry were documented and analysed across ages and gender. Results. The average BMMNC per ml in the age groups 0–20, 21–40, 41–60, and 61–80 years were 4.71, 4.03, 3.67, and 3.02 million and the CD34+ were 1.05%, 1.04%, 0.94%, and 0.93% respectively. The decline in CD34+ was sharp between 20–40 and 40–60 age groups. Females of reproductive age group had lesser CD34+. Conclusion. The BMMNC and CD34+ percentages decline with aging in SCI victims. Their lower values in females during reproductive age should be analysed for relevance to hormonal influence. This study offers reference values of BMMNC and CD34+ of SCI victims for successful clinical application.

Sign in / Sign up

Export Citation Format

Share Document